Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503821 | 0.81 | LCK (0.58) | LCKFYNCYP1A2LMNAAKR1C3 | |
| SCHEMBL3185974 | 0.81 | LCK (0.64) | LCKFYNCYP1A2LMNA | |
| SCHEMBL2511327 | 0.79 | MRGPRX4 (0.45) | LCKFYNMRGPRX4LMNAPLA2G2A | |
| SCHEMBL2170685 | 0.79 | MRGPRX4 (0.49) | MRGPRX4LMNAPLA2G2A | |
| Hydrochloric Acid SCHEMBL9436647 | 0.77 | SLC9A1 (0.42) | — | |
| SCHEMBL26146696 | 0.76 | LCK (0.41) | LCKFYNVNN1CYP1A2PTGS2 | |
| SCHEMBL26146699 | 0.76 | LCK (0.41) | LCKFYNCYP1A2LMNA | |
| Hydrochloric Acid SCHEMBL9040784 | 0.75 | VNN1 (0.36) | VNN1SIRT2LMNA | |
| SCHEMBL2160802 | 0.74 | TPMT (0.61) | MRGPRX4LMNAPLA2G2A | |
| SCHEMBL5619666 | 0.74 | CA12 (0.58) | LCKFYNCYP1A2PTGS2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| US-20050171092-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1274701-B1 | [1,4']-BIPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| EP-1274701-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
| WO-2001077101-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
| EP-0556674-B1 | 3,5-substituted benzoylguanidines with antiarrhythmic activity and cell proliferation inhibiting activity | HOECHST AG (DE) | 1996-06-19 | — | — | EP | disclosed |
| US-5373024-A | 3,5-Substituted benzoylguanidines, process for their preparation, their use as a medicament of diagnostic and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-12-13 | — | — | US | disclosed |
| EP-0556674-A1 | 3,5-substituted benzoylguanidines with antiarrhythmic activity and cell proliferation inhibiting activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | disclosed |
| US-3995044-A | Pyridine carboxylic acid amides for mycobacterium infections | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | LCK 447/4885FYN 2286/4885VNN1 3146/4885 |
| US-20050171092-A1 | Chemical compounds | CCR3, CCR1, CCR4 | LCK 427/4885FYN 2186/4885VNN1 3193/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | LCK 447/4885FYN 2286/4885VNN1 3146/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | LCK 447/4885FYN 2286/4885VNN1 3146/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | LCK 427/4885FYN 2186/4885VNN1 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.